CRISPR applications in ophthalmologic genome surgery
T Cabral, JE DiCarlo, S Justus… - Current opinion in …, 2017 - journals.lww.com
T Cabral, JE DiCarlo, S Justus, JD Sengillo, Y Xu, SH Tsang
Current opinion in ophthalmology, 2017•journals.lww.comOver the past year, CRISPR-Cas genome editing has been used to correct pathogenic
mutations in vivo and in transplantable stem cells. Although off-target mutagenesis remains
a concern, improvement in CRISPR-Cas technology and careful screening for undesired
mutations will likely lead to clinical eye therapeutics employing CRISPR-Cas systems in the
near future.
mutations in vivo and in transplantable stem cells. Although off-target mutagenesis remains
a concern, improvement in CRISPR-Cas technology and careful screening for undesired
mutations will likely lead to clinical eye therapeutics employing CRISPR-Cas systems in the
near future.
Summary
Over the past year, CRISPR-Cas genome editing has been used to correct pathogenic mutations in vivo and in transplantable stem cells. Although off-target mutagenesis remains a concern, improvement in CRISPR-Cas technology and careful screening for undesired mutations will likely lead to clinical eye therapeutics employing CRISPR-Cas systems in the near future.
Lippincott Williams & Wilkins